SCHEMBL1728538

SCHEMBL1728538

O=C(c1ccccc1)c1cn2ccccc2n1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.73
PTGS2 P35354 2/20 0.73
RAB9A P51151 9/20 0.61
NPC1 O15118 6/20 0.61
MAPT P10636 4/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
KDM4E B2RXH2 7/20 0.55
HPGD P15428 1/20 0.55
SMN1; SMN2 Q16637 4/20 0.51
TP53 P04637 1/20 0.50
PKM P14618 2/20 0.49
POLB P06746 2/20 0.48
ALDH1A1 P00352 2/20 0.48
GFER P55789 2/20 0.47
LMNA P02545 1/20 0.47
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
MIF P14174 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4217488 0.88 PTGS1 (0.60) PTGS1PTGS2RAB9ANPC1MAPT
SCHEMBL4225362 0.88 RAB9A (0.67) PTGS1PTGS2RAB9ANPC1MAPT
SCHEMBL118449 0.84 PTGS1 (1.00) PTGS1PTGS2RAB9ANPC1MAPT
SCHEMBL2334973 0.83 PTGS1 (0.96) PTGS1PTGS2RAB9ANPC1MAPT
Water SCHEMBL21708935 0.83 PTGS1 (0.96) PTGS1PTGS2RAB9ANPC1MAPT
Bromide SCHEMBL570786 0.83 PTGS1 (0.96) PTGS1PTGS2RAB9ANPC1MAPT
Hydrochloric Acid SCHEMBL8878519 0.83 PTGS1 (0.96) PTGS1PTGS2RAB9ANPC1MAPT
SCHEMBL1728496 0.83 PTGS1 (0.50) PTGS1PTGS2RAB9ANPC1MAPT
SCHEMBL2087427 0.81 PTGS1 (0.49) PTGS1PTGS2RAB9ANPC1MAPT
SCHEMBL2085892 0.81 RAB9A (0.50) PTGS1PTGS2RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262805-B1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-22 EP disclosed
EP-2225240-B1 Derivatives of 6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof SANOFI SA (FR) 2014-01-22 EP disclosed
EP-2260033-B1 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI SA (FR) 2011-11-23 EP disclosed
EP-2260033-B1 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI SA (FR) 2011-11-23 EP disclosed
EP-2225245-B1 N-phenyl-imidazo(1,2-a)pyridine-2-carboxamide compounds, preparation thereof and therapeutic application thereof SANOFI SA (FR) 2011-10-19 EP disclosed
US-20100317620-A1 N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US disclosed
US-20100317687-A1 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US disclosed
US-20100317687-A1 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US disclosed
US-20100317688-A1 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US disclosed
CN-101910174-A 2-benzoylimidazo [1,2-a ] pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI AVENTIS 2010-12-08 CN disclosed
EP-2040703-B1 DERIVATIVES OF 2-BENZOYL-IMIDAZOPYRIDINES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2009-10-21 EP disclosed
US-20090143421-A1 USE OF 2-BENZOYL-IMIDAZOPYRIDINES IN THERAPEUTICS SANOFI-AVENTIS (FR) 2009-06-04 US disclosed
US-4352804-A ANTIULCER AGENTS, GASTROINTESTINAL DISORDERS ACF CHEMIEFARMA NV (NL) 1982-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317688-A1 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF XDH, CYP11B2, IL4I1 PTGS1 742/4885PTGS2 846/4885RAB9A 1356/4885
US-20100317687-A1 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF XDH, REN, GLS PTGS1 1046/4885PTGS2 1343/4885RAB9A 1587/4885
US-20100317620-A1 N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION AND THERAPEUTIC USE THEREOF GLS, REN, XDH PTGS1 1688/4885PTGS2 1923/4885RAB9A 1438/4885
US-20090143421-A1 USE OF 2-BENZOYL-IMIDAZOPYRIDINES IN THERAPEUTICS NCOR1, NR4A3, NR4A2 PTGS1 2541/4885PTGS2 2339/4885RAB9A 3315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.